Lock in 2023 pricing and receive immediate shipment of annotated PBMCs, plasma, and serum specimens that will take your biomarker investigation to the next level. Peruse our inventory of 35 confirmed disease conditions (inflammatory, metabolic, cancer, and respiratory) plus healthy donors.
While patient engagement is a critical component of translational precision medicine, in practice patients themselves are underutilized in the therapy development process. Read how a direct-to-patient approach to prospective specimen collection addresses the translation gap in our latest white paper.
Protein assays are a hallmark of the translational process that turns bench discoveries into bedside treatments. Read how such methods can be enhanced through the standardization of biospecimen procurement to improve sample consistency, patient access, and regulatory compliance.
SLAS2024: Tackling variability and inefficiency in therapy development
Attending SLAS2024 February 5-7 at the Boston Convention Center? Visit booth 469 to find out how Sanguine’s direct-to-patient approach to procuring leukopaks and other diverse biospecimens powers biomarker studies and accelerate precision translational medicine and cell & gene therapy development.